We are pleased to invite you to the TAPI Boost Seminar, a focused half-day event designed for R&D, CMC, Regulatory Affairs and procurement professionals who would like a better understanding of the pharmaceutical active ingredient (APIs) world and the future of pharmaceutical development. As one of the world’s leading API suppliers, TAPI brings more than eight decades of scientific excellence, supported by more than 4,100 experts, a portfolio of more than 350 APIs, and a global presence in more than 100 countries.
This seminar will take you inside the scientific, technical and regulatory considerations that determine API success, including polymorph selection and particle engineering, complex peptides development and oligonucleotide control strategies, smooth scale-up to large scale production. Participants will gain practical insights, development tools and real-world case studies that help secure robust API performance, reduce formulation risk, and accelerate the path to market.
Join us to learn what truly matters in API development, how to anticipate and control the parameters that can make or break your formulation, and how new technologies are shaping the next generation of drug substances. This is an opportunity to connect with experts, exchange experiences, and elevate your development strategy with knowledge grounded in decades of API leadership.
To learn mere about TAPI, please visit the TAPI website at www.tapi.com
Date: Tuesday, 17 March 2026
Time: 8:15 – 12:30
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:15 | Networking, registration and light breakfast |
| 8:45 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 8:50 | Introduction to TAPI and TAPI R&D |
| 9:10 | Polymorph search and solid-state development |
| 9:30 | Critical solid-state properties |
| 10:10 | Q&A and transition |
| 10:20 | Coffee Break |
| 10:40 | Complexity of GLP 1 development |
| 11:10 | Recombinant peptide development |
| 11:25 | Diastereomeric distribution in oligonucleotides |
| 11:40 | Small molecule development strategy |
| 12:10 | Advanced Steroid development |
| 12:20 | Closing remarks |
| 12:30 | Light lunch |
Speakers
 |
Nir Koyfman, Head of Sales for Northern Europe and the Middle East, TAPI
Nir Koyfman, M.Sc. and MBA, is Head of Sales for Northern Europe and the Middle East with more than 20 years of experience in the API industry across high potent APIs, peptides, synthetic and fermentation-based drug substances, and steroids. Nir supports global customers ranging from early-stage startups to established commercial pharmaceutical companies, providing tailored guidance, personalized technical assistance, and strategic support throughout drug development. |
 |
Paolo Tiseni, Senior Director, Head of New Products Management R&D, TAPI
Paolo Tiseni is Senior Director, Head of New Products Management, in TAPI’s Global R&D team. Paolo has extensive experience in chemical process R&D, technology transfer and CDMO field, acquired in TAPI and other pharmaceutical companies over the years. Paolo holds a PhD in Organic Chemistry from ETH Zürich and a Post Doc from Harvard University. |
 |
Pavel Kolesa, Senior Manager, Physical R&D, TAPI
Pavel Kolesa is a Senior Manager of the Physical R&D department at TAPI with more than 10 years of experience in solid state science applied to API development. His work focuses on advancing physical characterization and crystallization sciences, while leading the solid state group in supporting API development. Pavel graduated in Medicinal Chemistry from the Brno University of Technology.
|
| Organized by | In collaboration with |
 |
 |